Defining lines of therapy in haematological malignancies: a proposed systematic and comprehensive framework from the EBMT Practice Harmonisation and Guidelines Committee - Scorecard - MDSpire
Advertisement
Defining lines of therapy in haematological malignancies: a proposed systematic and comprehensive framework from the EBMT Practice Harmonisation and Guidelines Committee
Clinical Scorecard: Establishing a Comprehensive Framework for Therapy Lines in Hematological Malignancies: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee
At a Glance
Category
Detail
Condition
Key Mechanisms
Targeted therapies, immunotherapy, and cellular therapies (source needed)
Target Population
Patients with acute leukemias, lymphomas, and multiple myeloma (source needed)
Care Setting
Key Highlights
Standardized framework for defining lines of therapy (LoT) developed by EBMT (source needed)
LoT defined as a coherent therapeutic episode aimed at disease control (source needed)
New LoT assigned at documented progression, relapse, or introduction of a new agent (source needed)
Bridging therapies prior to cellular therapy considered part of the same LoT (source needed)
Aim to enhance methodological rigor and improve treatment reporting (source needed)
Guideline-Based Recommendations
Diagnosis
Standardized definitions of LoT to improve clarity in treatment reporting (source needed)
Management
Utilization of consensus-based criteria for LoT determination (source needed)
Monitoring & Follow-up
Harmonization of data collection across studies and registries (source needed)
Risks
Potential misclassification due to variability in LoT definitions (source needed)
Patient & Prescribing Data
Patients with hematological malignancies undergoing therapy
Incorporation of complex combinations and novel modalities in treatment strategies
Clinical Best Practices
Adhere to standardized definitions for LoT to enhance clinical care (source needed)
Implement uniformity in LoT classification to support evidence-based decision-making (source needed)
Engage in continuous education on emerging therapies and their integration into practice (source needed)
by Alessandro Criscimanna, Jacques-Emanuel Galimard, Isabel Sánchez-Ortega, Patrick J. Hayden, Laurent Garderet, Anna Sureda, Fabio Ciceri, Donal P. McLornan, Krzysztof Kałwak, Antonio M. Risitano, Francesco Onida, Ibrahim Yakoub-Agha, Ali Bazarbachi, Annalisa Ruggeri
